Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CryoLife tissue infections

This article was originally published in The Gray Sheet

Executive Summary

CDC issues morbity and mortality report identifying cases of allograft-associated bacterial infection March 14. Of 26 named cases, 14 were identified as using CryoLife-processed tissues. "Some of the infections are likely not due to the tissue," CryoLife President/CEO Steven Anderson maintained during a March 15 teleconference downplaying the report and emphasizing that it is a summary of previously released information. Though a measure of increased oversight by FDA is anticipated, the firm says it is not aware of "serious" infections of the rare bacterium Clostridium sordellii since a 23-year old Minnesota knee surgery patient implanted with Cryolife-processed human donor condyle tissue died Nov. 11, 2001 (1"The Gray Sheet" Dec. 24, 2001, In Brief)...

You may also be interested in...



RTI Expanded Use Of BioCleanse To Soft Tissues Spurred By CDC Report

Regeneration Technologies, Inc. plans to be fully processing its soft tissue product lines with BioCleanse by late August

Cryolife

CDC confirms presence of rare bacterium Clostridium sordellii in Cryolife-processed human donor condyle tissue implanted in a 23-year old Minnesota knee surgery patient who died Nov. 11; the bacterium was not found or implicated in two other Minnesota total knee replacement patient deaths. Cryolife does not intend to alter its processing protocols after CDC, FDA and the Minnesota Department of Health found no connection between the deaths and made no recommendations for changes (1"The Gray Sheet" Dec. 10, 2001, In Brief)...

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016246

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel